Animal cells use a wide variety of mechanisms to slow or prevent replication of viruses. These mechanisms are usually mediated by antiviral proteins whose expression and activities can be constitutive but are frequently amplified by interferon induction. Among these interferon-stimulated proteins, members of the IFITM (ntereron-nduced ransembrane) family are unique because they prevent infection before a virus can traverse the lipid bilayer of the cell. At least three human IFITM proteins—IFITM1, IFITM2, and IFITM3—have antiviral activities. These activities limit infection in cultured cells by many viruses, including dengue virus, Ebola virus, influenza A virus, severe acute respiratory syndrome coronavirus, and West Nile virus. Murine Ifitm3 controls influenza A virus infection in vivo, and polymorphisms in human correlate with the severity of both seasonal and highly pathogenic avian influenza virus. Here we review the discovery and characterization of the IFITM proteins, describe the spectrum of their antiviral activities, and discuss potential mechanisms underlying these effects.


Article metrics loading...

Loading full text...

Full text loading...


Literature Cited

  1. Diamond MS, Farzan M. 1.  2013. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat. Rev. Immunol. 13:46–57 [Google Scholar]
  2. Duggal NK, Emerman M. 2.  2012. Evolutionary conflicts between viruses and restriction factors shape immunity. Nat. Rev. Immunol. 12:687–95 [Google Scholar]
  3. Bieniasz PD. 3.  2004. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5:1109–15 [Google Scholar]
  4. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT. 4.  et al. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481–85 [Google Scholar]
  5. Friedman RL, Manly SP, McMahon M, Kerr IM, Stark GR. 5.  1984. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell 38:745–55 [Google Scholar]
  6. Reid LE, Brasnett AH, Gilbert CS, Porter AC, Gewert DR. 6.  et al. 1989. A single DNA response element can confer inducibility by both α- and γ-interferons. Proc. Natl. Acad. Sci. USA 86:840–44 [Google Scholar]
  7. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN. 7.  et al. 2009. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139:1243–54IFITM proteins restrict IAV and flavivirus entry. [Google Scholar]
  8. Lange UC, Saitou M, Western PS, Barton SC, Surani MA. 8.  2003. The fragilis interferon-inducible gene family of transmembrane proteins is associated with germ cell specification in mice. BMC Dev. Biol. 3:1 [Google Scholar]
  9. Deblandre GA, Marinx OP, Evans SS, Majjaj S, Leo O. 9.  et al. 1995. Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. J. Biol. Chem. 270:23860–66 [Google Scholar]
  10. Takahashi S, Doss C, Levy S, Levy R. 10.  1990. TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. J. Immunol. 145:2207–13 [Google Scholar]
  11. Bradbury LE, Kansas GS, Levy S, Evans RL, Tedder TF. 11.  1992. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Immunol. 149:2841–50 [Google Scholar]
  12. Matsumoto AK, Martin DR, Carter RH, Klickstein LB, Ahearn JM, Fearon DT. 12.  1993. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J. Exp. Med. 178:1407–17 [Google Scholar]
  13. Evans SS, Lee DB, Han T, Tomasi TB, Evans RL. 13.  1990. Monoclonal antibody to the interferon-inducible protein Leu-13 triggers aggregation and inhibits proliferation of leukemic B cells. Blood 76:2583–93 [Google Scholar]
  14. Chen YX, Welte K, Gebhard DH, Evans RL. 14.  1984. Induction of T cell aggregation by antibody to a 16kd human leukocyte surface antigen. J. Immunol. 133:2496–501 [Google Scholar]
  15. Frey M, Appenheimer MM, Evans SS. 15.  1997. Tyrosine kinase–dependent regulation of L-selectin expression through the Leu-13 signal transduction molecule: evidence for a protein kinase C–independent mechanism of L-selectin shedding. J. Immunol. 158:5424–34 [Google Scholar]
  16. Tanaka SS, Matsui Y. 16.  2002. Developmentally regulated expression of mil-1 and mil-2, mouse interferon-induced transmembrane protein like genes, during formation and differentiation of primordial germ cells. Mech. Dev. 119:Suppl. 1S261–67 [Google Scholar]
  17. Saitou M, Barton SC, Surani MA. 17.  2002. A molecular programme for the specification of germ cell fate in mice. Nature 418:293–300 [Google Scholar]
  18. Tanaka SS, Yamaguchi YL, Tsoi B, Lickert H, Tam PP. 18.  2005. IFITM/Mil/fragilis family proteins IFITM1 and IFITM3 play distinct roles in mouse primordial germ cell homing and repulsion. Dev. Cell 9:745–56 [Google Scholar]
  19. Lange UC, Adams DJ, Lee C, Barton S, Schneider R. 19.  et al. 2008. Normal germ line establishment in mice carrying a deletion of the Ifitm/fragilis gene family cluster. Mol. Cell. Biol. 28:4688–96 [Google Scholar]
  20. Alber D, Staeheli P. 20.  1996. Partial inhibition of vesicular stomatitis virus by the interferon-induced human 9-27 protein. J. Interferon Cytokine Res. 16:375–80 [Google Scholar]
  21. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM. 21.  et al. 2011. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 7:e1001258IFITM proteins have distinct antiviral signatures; fusion site may underlie differences in IFITM protein sensitivity. [Google Scholar]
  22. Zhu H, Liu C. 22.  2003. Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. J. Virol. 77:5493–98 [Google Scholar]
  23. Shapira SD, Gat-Viks I, Shum BO, Dricot A, de Grace MM. 23.  et al. 2009. A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell 139:1255–67 [Google Scholar]
  24. Almen MS, Bringeland N, Fredriksson R, Schioth HB. 24.  2012. The dispanins: a novel gene family of ancient origin that contains 14 human members. PLoS ONE 7:e31961 [Google Scholar]
  25. Zhang Z, Liu J, Li M, Yang H, Zhang C. 25.  2012. Evolutionary dynamics of the interferon-induced transmembrane gene family in vertebrates. PLoS ONE 7:e49265 [Google Scholar]
  26. Smith SE, Gibson MS, Wash RS, Ferrara F, Wright E. 26.  et al. 2013. Chicken interferon-inducible transmembrane protein 3 restricts influenza viruses and lyssaviruses in vitro. J. Virol. 87:12957–66 [Google Scholar]
  27. Hickford D, Frankenberg S, Shaw G, Renfree MB. 27.  2012. Evolution of vertebrate interferon inducible transmembrane proteins. BMC Genomics 13:155 [Google Scholar]
  28. Johnson MC, Sangrador-Vegas A, Smith TJ, Cairns MT. 28.  2006. Cloning and characterization of two genes encoding rainbow trout homologues of the IFITM protein family. Vet. Immunol. Immunopathol. 110:357–62 [Google Scholar]
  29. Moffatt P, Gaumond MH, Salois P, Sellin K, Bessette MC. 29.  et al. 2008. Bril: a novel bone-specific modulator of mineralization. J. Bone Miner. Res. 23:1497–508 [Google Scholar]
  30. Hanagata N, Li X, Morita H, Takemura T, Li J, Minowa T. 30.  2011. Characterization of the osteoblast-specific transmembrane protein IFITM5 and analysis of IFITM5-deficient mice. J. Bone Miner. Metab. 29:279–90 [Google Scholar]
  31. Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ. 31.  et al. 2012. A single recurrent mutation in the 5′-UTR of IFITM5 causes osteogenesis imperfecta type V. Am. J. Hum. Genet. 91:343–48 [Google Scholar]
  32. Semler O, Garbes L, Keupp K, Swan D, Zimmermann K. 32.  et al. 2012. A mutation in the 5′-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. Am. J. Hum. Genet. 91:349–57 [Google Scholar]
  33. Everitt AR, Clare S, Pertel T, John SP, Wash RS. 33.  et al. 2012. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484:519–23Human IFITM3 SNP correlates with severity of influenza; Ifitm3−/− mice are highly susceptible to influenza. [Google Scholar]
  34. Bailey CC, Huang IC, Kam C, Farzan M. 34.  2012. Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog. 8:e1002909Ifitm3 is expressed constitutively in vivo; Ifitm3, but not other Ifitm proteins, attenuates influenza in mice. [Google Scholar]
  35. Zhang YH, Zhao Y, Li N, Peng YC, Giannoulatou E. 35.  et al. 2013. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat. Commun. 4:1418 [Google Scholar]
  36. Wang Z, Zhang A, Wan Y, Liu X, Qiu C. 36.  et al. 2014. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc. Natl. Acad. Sci. USA 111:769–74 [Google Scholar]
  37. Mills TC, Rautanen A, Elliott KS, Parks T, Naranbhai V. 37.  et al. 2013. IFITM3 and susceptibility to respiratory viral infections in the community. J. Infect. Dis. 209:1028–31 [Google Scholar]
  38. Wakim LM, Gupta N, Mintern JD, Villadangos JA. 38.  2013. Enhanced survival of lung tissue-resident memory CD8+ T cells during infection with influenza virus due to selective expression of IFITM3. Nat. Immunol. 14:238–45 [Google Scholar]
  39. Wakim LM, Woodward-Davis A, Liu R, Hu Y, Villadangos J. 39.  et al. 2012. The molecular signature of tissue resident memory CD8 T cells isolated from the brain. J. Immunol. 189:3462–71 [Google Scholar]
  40. Jiang D, Weidner JM, Qing M, Pan XB, Guo H. 40.  et al. 2010. Identification of five interferon-induced cellular proteins that inhibit West Nile virus and dengue virus infections. J. Virol. 84:8332–41 [Google Scholar]
  41. John SP, Chin CR, Perreira JM, Feeley EM, Aker AM. 41.  et al. 2013. The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J. Virol. 87:7837–52 [Google Scholar]
  42. Huang IC, Bosch BJ, Li F, Li W, Lee KH. 42.  et al. 2006. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J. Biol. Chem. 281:3198–203 [Google Scholar]
  43. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. 43.  2005. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:1643–45 [Google Scholar]
  44. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK. 44.  et al. 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450–54 [Google Scholar]
  45. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT. 45.  2010. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J. Virol. 84:12646–57 [Google Scholar]
  46. Mudhasani R, Tran JP, Retterer C, Radoshitzky SR, Kota KP. 46.  et al. 2013. IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J. Virol. 87:8451–64 [Google Scholar]
  47. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C. 47.  2011. The IFITM proteins inhibit HIV-1 infection. J. Virol. 85:2126–37 [Google Scholar]
  48. Chutiwitoonchai N, Hiyoshi M, Hiyoshi-Yoshidomi Y, Hashimoto M, Tokunaga K, Suzu S. 48.  2013. Characteristics of IFITM, the newly identified IFN-inducible anti-HIV-1 family proteins. Microbes Infect. 15:280–90 [Google Scholar]
  49. Yount JS, Karssemeijer RA, Hang HC. 49.  2012. S-Palmitoylation and ubiquitination differentially regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated resistance to influenza virus. J. Biol. Chem. 287:19631–41Ubiquitylation and palmitoylation of IFITM3 regulate localization, expression, and restriction activity. [Google Scholar]
  50. Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. 50.  2011. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J. Virol. 85:12881–89 [Google Scholar]
  51. Wilkins C, Woodward J, Lau DT, Barnes A, Joyce M. 51.  et al. 2013. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 57:461–69 [Google Scholar]
  52. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. 52.  2002. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J. Virol. 76:5654–66 [Google Scholar]
  53. Anafu AA, Bowen CH, Chin CR, Brass AL, Holm GH. 53.  2013. Interferon-inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry. J. Biol. Chem. 288:17261–71 [Google Scholar]
  54. Chandran K, Farsetta DL, Nibert ML. 54.  2002. Strategy for nonenveloped virus entry: a hydrophobic conformer of the reovirus membrane penetration protein μ1 mediates membrane disruption. J. Virol. 76:9920–33 [Google Scholar]
  55. Ebert DH, Deussing J, Peters C, Dermody TS. 55.  2002. Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells. J. Biol. Chem. 277:24609–17 [Google Scholar]
  56. Chandran K, Nibert ML. 56.  1998. Protease cleavage of reovirus capsid protein μ1/μ1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subvirion particle. J. Virol. 72:467–75 [Google Scholar]
  57. Everitt AR, Clare S, McDonald JU, Kane L, Harcourt K. 57.  et al. 2013. Defining the range of pathogens susceptible to Ifitm3 restriction using a knockout mouse model. PLoS ONE 8:e80723 [Google Scholar]
  58. Smith RA, Young J, Weis JJ, Weis JH. 58.  2006. Expression of the mouse fragilis gene products in immune cells and association with receptor signaling complexes. Genes Immun. 7:113–21 [Google Scholar]
  59. Li K, Markosyan RM, Zheng YM, Golfetto O, Bungart B. 59.  et al. 2013. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog. 9:e1003124IFITM proteins decrease membrane fluidity and inhibit viral entry protein–mediated syncytium formation. [Google Scholar]
  60. Jia R, Pan Q, Ding S, Rong L, Liu SL. 60.  et al. 2012. The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. J. Virol. 86:13697–707Phosphorylation of Tyr20 regulates IFITM3 internalization. [Google Scholar]
  61. Hach JC, McMichael T, Chesarino NM, Yount JS. 61.  2013. Palmitoylation on conserved and nonconserved cysteines of murine IFITM1 regulates its stability and anti–influenza A virus activity. J. Virol. 87:9923–27 [Google Scholar]
  62. Bailey CC, Kondur HR, Huang IC, Farzan M. 62.  2013. Interferon-induced transmembrane protein 3 is a type II transmembrane protein. J. Biol. Chem. 288:32184–93Ifitm3 adopts at least two transmembrane topologies but is primarily a type II transmembrane protein. [Google Scholar]
  63. Yount JS, Moltedo B, Yang YY, Charron G, Moran TM. 63.  et al. 2010. Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. Nat. Chem. Biol. 6:610–14 [Google Scholar]
  64. Shan Z, Han Q, Nie J, Cao X, Chen Z. 64.  et al. 2013. Negative regulation of interferon-induced transmembrane protein 3 by SET7-mediated lysine monomethylation. J. Biol. Chem. 288:35093–103 [Google Scholar]
  65. Brem R, Oraszlan-Szovik K, Foser S, Bohrmann B, Certa U. 65.  2003. Inhibition of proliferation by 1-8U in interferon-α-responsive and non-responsive cell lines. Cell. Mol. Life Sci. 60:1235–48 [Google Scholar]
  66. Zucchi I, Prinetti A, Scotti M, Valsecchi V, Valaperta R. 66.  et al. 2004. Association of rat8 with Fyn protein kinase via lipid rafts is required for rat mammary cell differentiation in vitro. Proc. Natl. Acad. Sci. USA 101:1880–85 [Google Scholar]
  67. Feeley EM, Sims JS, John SP, Chin CR, Pertel T. 67.  et al. 2011. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog. 7:e1002337 [Google Scholar]
  68. Amini-Bavil-Olyaee S, Choi YJ, Lee JH, Shi M, Huang IC. 68.  et al. 2013. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe 13:452–64IFITM3 expression causes cholesterol accumulation in endolysosomal organelles, possibly due to IFITM3-VAPA interaction. [Google Scholar]
  69. Jia R, Xu F, Qian J, Yao Y, Miao C. 69.  et al. 2014. Identification of an endocytic signal essential for the antiviral action of IFITM3. Cell. Microbiol. 161080–93 [Google Scholar]
  70. Xu Y, Yang G, Hu G. 70.  2009. Binding of IFITM1 enhances the inhibiting effect of caveolin-1 on ERK activation. Acta Biochim. Biophys. Sin. 41:488–94 [Google Scholar]
  71. Oldenburg J, Reignier T, Flanagan ML, Hamilton GA, Cannon PM. 71.  2007. Differences in tropism and pH dependence for glycoproteins from the clade B1 arenaviruses: implications for receptor usage and pathogenicity. Virology 364:132–39 [Google Scholar]
  72. van der Schaar HM, Rust MJ, Chen C, van der Ende-Metselaar H, Wilschut J. 72.  et al. 2008. Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells. PLoS Pathog. 4:e1000244 [Google Scholar]
  73. Rojek JM, Sanchez AB, Nguyen NT, de la Torre JC, Kunz S. 73.  2008. Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J. Virol. 82:7677–87 [Google Scholar]
  74. Pasqual G, Rojek JM, Masin M, Chatton JY, Kunz S. 74.  2011. Old World arenaviruses enter the host cell via the multivesicular body and depend on the endosomal sorting complex required for transport. PLoS Pathog. 7:e1002232 [Google Scholar]
  75. Lin TY, Chin CR, Everitt AR, Clare S, Perreira JM. 75.  et al. 2013. Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. Cell Rep. 5:895–908Amphotericin B prevents IFITM3-mediated restriction of IAV. [Google Scholar]

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error